Conference coverage

Stay up to date with the latest developments in PBC with content from key international congresses, video discussions and breaking news stories.

EASL 2024

Filter – EASL 2024

Combination therapies and real world treatment for PBC patients

Dr Adriaan Van der Meer shares his insights on the results from the combination trial of obeticholic acid and bezafibrate for PBC patients, presented at EASL 2024 in Milan, Italy. In addition, discover key findings and learn about the RECAPITULATE trial, focusing on real-world treatment outcomes.

Breaking analysis of ASSURE from EASL 2024

Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.

ELATIVE updates from EASL 2024

Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.

‘Rapid and durable response’ with seladelpar in patients with PBC and cirrhosis

ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.

Biochemical response benefits with elafibranor are ‘consistent’ for PBC

ELATIVE subanalysis confirms improved biochemical response with elafibranor over placebo for primary biliary cholangitis according to various different criteria.

Adding obeticholic acid to slow-release bezafibrate shows promise for PBC

Combining slow-release bezafibrate with obeticholic acid shows treatment potential for patients with primary biliary cholangitis.

ELATIVE trial shows pruritus benefits with elafibranor in PBC

ELATIVE trial results for pruritus show benefits for both severity and impact on the quality of life of patients with primary biliary cholangitis.

The Liver Meeting 2023

Filter – The Liver Meeting 2023

Andreas Kremer discusses advances in second-line obeticholic acid

Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.

Kris Kowdley’s analysis of breakthrough research on PBC

Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.

Gideon Hirschfield highlights noteworthy findings on PBC

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.

Complete biochemical and POISE response seen with second-line OCA in real-world setting

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.

ELATIVE: Elafibranor shows treatment efficacy in patients with PBC

ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.

Positive RESPONSE for seladelpar in patients with PBC

RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.

Denosumab performs well against bisphosphonate for PBC-related osteoporosis

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.

Adding bezafibrate to OCA shows treatment promise for PBC

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.

Feedback

Your feedback helps us create the most relevant independent programs for your learning needs in the future.